T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease - PubMed (original) (raw)
. 1998 Feb 1;91(3):1083-90.
M H Carabasi, H Castro-Malaspina, B H Childs, S Mackinnon, F Boulad, A P Gillio, N A Kernan, T N Small, P Szabolcs, J Taylor, J Yahalom, N H Collins, S A Bleau, P M Black, G Heller, R J O'Reilly, J W Young
Affiliations
- PMID: 9446672
Free article
T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease
E B Papadopoulos et al. Blood. 1998.
Free article
Abstract
Thirty-one consecutive patients with acute myelogenous leukemia (AML) in first complete remission and 8 with AML in second complete remission received T cell-depleted allogeneic bone marrow transplants from HLA-identical sibling donors. Patients received myeloablative cytoreduction consisting of hyperfractionated total body irradiation, thiotepa, and cyclophosphamide. Those patients at risk for immune-mediated graft rejection received additional immune suppression with antithymocyte globulin and methylprednisolone in the early peritransplant period. Patients with AML who underwent allogeneic T-cell-depleted bone marrow transplantations (BMT) in first or second remission have achieved respective disease-free survival (DFS) probabilities of 77% (median follow-up at approximately 56 months) and 50% (median follow-up at approximately 48 months). Ten of 31 patients transplanted in first remission were > or = 40 years old and have attained a DFS at 4 years of 70%. For patients with AML transplanted in first or second remission, the respective cause-specific probabilities of relapse were 3.2% or 12.5%, and those of nonleukemic mortality were 19.4% or 37.5%. There were no cases of immune-mediated graft rejection and no cases of grade II to IV acute graft-versus-host disease (GVHD). All survivors enjoy Karnofsky performance scores (KPS) of 100%, except 2 patients with KPS of 80% to 90%. T-cell-depleted allogeneic BMT can provide durable DFS together with an excellent performance status in the majority of patients with de novo AML. In addition, GVHD is not an obligatory correlate of the graft-versus-leukemia benefit or freedom from relapse afforded by allogeneic BMT administered as postremission therapy for AML. This study provides a basis for prospective comparison with other postremission therapies considered standard in the management of patients with this disease.
Similar articles
- T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission.
Young JW, Papadopoulos EB, Cunningham I, Castro-Malaspina H, Flomenberg N, Carabasi MH, Gulati SC, Brochstein JA, Heller G, Black P, et al. Young JW, et al. Blood. 1992 Jun 15;79(12):3380-7. Blood. 1992. PMID: 1596577 - CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J. Soiffer RJ, et al. Blood. 1997 Apr 15;89(8):3039-47. Blood. 1997. PMID: 9108425 Clinical Trial. - Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia.
Aversa F, Terenzi A, Carotti A, Felicini R, Jacucci R, Zei T, Latini P, Aristei C, Santucci A, Martelli MP, Cunningham I, Reisner Y, Martelli MF. Aversa F, et al. J Clin Oncol. 1999 May;17(5):1545-50. doi: 10.1200/JCO.1999.17.5.1545. J Clin Oncol. 1999. PMID: 10334542 - Bone marrow transplantation for acute leukemia: recent advances and comparison with alternative therapies.
Champlin R, Gale RP. Champlin R, et al. Semin Hematol. 1987 Jan;24(1):55-67. Semin Hematol. 1987. PMID: 3547673 Review.
Cited by
- Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis.
Cho C, Devlin S, Maloy M, Horowitz MM, Logan B, Rizzo JD, Giralt SA, Perales MA. Cho C, et al. Bone Marrow Transplant. 2023 Oct;58(10):1089-1095. doi: 10.1038/s41409-023-02031-2. Epub 2023 Jul 8. Bone Marrow Transplant. 2023. PMID: 37422574 Free PMC article. - Prevalence of the BCR/ABL fusion gene and T cell stimulation capacity of dendritic cells in chronic myelogenous leukemia.
Gaafar A, Al-Omar HM, Manogaran PS, Almohareb F, Alhussein K. Gaafar A, et al. Am J Transl Res. 2023 Feb 15;15(2):967-981. eCollection 2023. Am J Transl Res. 2023. PMID: 36915720 Free PMC article. - Impact of total marrow/lymphoid irradiation dose to the intestine on graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
Saldi S, Fulcheri CPL, Zucchetti C, Abdelhamid AMH, Carotti A, Pierini A, Ruggeri L, Tricarico S, Chiodi M, Ingrosso G, Bini V, Velardi A, Martelli MF, Hui SK, Aristei C. Saldi S, et al. Front Oncol. 2022 Dec 8;12:1035375. doi: 10.3389/fonc.2022.1035375. eCollection 2022. Front Oncol. 2022. PMID: 36568236 Free PMC article. - Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34+-selected allogeneic transplantation.
Cho C, Hilden P, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, Gyurkocza B, Jakubowski AA, Maloy MA, O'Reilly RJ, Papadopoulos EB, Peled JU, Ponce DM, Shaffer B, Tamari R, van den Brink MRM, Young JW, Barba P, Perales MA. Cho C, et al. Adv Cell Gene Ther. 2021 Jan;4(1):e103. doi: 10.1002/acg2.103. Epub 2020 Sep 25. Adv Cell Gene Ther. 2021. PMID: 36339371 Free PMC article. - Chimerism analysis for clinicians: a review of the literature and worldwide practices.
Blouin AG, Askar M. Blouin AG, et al. Bone Marrow Transplant. 2022 Mar;57(3):347-359. doi: 10.1038/s41409-022-01579-9. Epub 2022 Jan 26. Bone Marrow Transplant. 2022. PMID: 35082369 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials